Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

© Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ. Background: Antibiotic over prescription for upper respiratory tract infections (URTIs) in primary care exacerbates antimicrobial resistance. There is a need for effective alternatives to antibiotic prescribing. Honey is a lay remedy for URTIs, and has an emerging evidence base for its use. Honey has antimicrobial properties, and guidelines recommended honey for acute cough in children. Objectives: To evaluate the effectiveness of honey for symptomatic relief in URTIs. Methods: A systematic review and meta-analysis. We searched Pubmed, Embase, Web of Science, AMED, Cab abstracts, Cochrane Library, LILACS, and CINAHL with a combination of keywords and MeSH terms. Results: We identified 1345 unique records, and 14 studies were included. Overall risk of bias was moderate. Compared with usual care, honey improved combined symptom score (three studies, mean difference-3.96, 95% CI-5.42 to-2.51, I2=0%), cough frequency (eight studies, standardised mean difference (SMD)-0.36, 95% CI-0.50 to-0.21, I2=0%) and cough severity (five studies, SMD-0.44, 95% CI-0.64 to-0.25, I2=20%). We combined two studies comparing honey with placebo for relieving combined symptoms (SMD-0.63, 95% CI-1.44 to 0.18, I2=91%). Conclusions: Honey was superior to usual care for the improvement of symptoms of upper respiratory tract infections. It provides a widely available and cheap alternative to antibiotics. Honey could help efforts to slow the spread of antimicrobial resistance, but further high quality, placebo controlled trials are needed. PROSPERO registration No: Study ID, CRD42017067582 on PROSPERO: International prospective register of systematic reviews (https://www.crd.york.ac.uk/prospero/).

Original publication

DOI

10.1136/bmjebm-2020-111336

Type

Journal article

Journal

BMJ Evidence-Based Medicine

Publication Date

01/01/2020